Cediranib - AstraZeneca

Drug Profile

Cediranib - AstraZeneca

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; Institute of Cancer Research; Mario Negri Institute for Pharmacological Research; National Cancer Institute (Canada); National Cancer Institute (USA); Royal Marsden NHS Foundation Trust; University Health Network; University of Manchester; University of Oxford
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Mesothelioma; Prostate cancer; Solid tumours
  • Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 29 Jul 2018 Institute of Cancer Research and Royal Marsden NHS Foundation Trust completes the CASPS phase II trial in Alveolar soft part sarcoma (Metastatic disease, In adolescents, In the elderly, In adults) in Australia, Spain, United Kingdom, Italy, Germany, France (PO) (ISRCTN63733470)
  • 01 Jun 2018 AstraZeneca completes the phase II e-Volve trial in Ovarian cancer in Canada (PO) (NCT02340611)
  • 01 Jun 2018 Interim adverse events and efficacy data from the phase II trial for Alveolar soft part sarcoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top